The board's rejection of acquisition proposals at $4.00-$4.25/share removes a near-term liquidity event, while cash burn ($28.4M operating cash outflow) and declining revenue fundamentals suggest continued downside risk. Monitor for further inbound M&A interest or potential capital raise given cash runway concerns.
Price Chart
Executive Summary
PetMed Express reported Q4 FY2026 net sales of $42.8M (-15.6% YoY) and a net loss of $4.1M ($0.19/share), narrowing from a $11.6M loss in the prior year. The company's full-year revenue fell 21.1% to $179M, with a net loss of $57.3M driven by a $26.7M goodwill impairment and $4.5M in whistleblower investigation costs. The board rejected two acquisition proposals at $4.00-$4.25/share, opting to remain independent.
Key Financial Metrics
Key Facts
- Q4 FY2026 net sales $42.8M, down 15.6% YoY from $50.8M
- Full-year FY2026 net sales $179.0M, down 21.1% YoY from $227.0M
- Q4 net loss $4.1M ($0.19/diluted share) vs $11.6M loss ($0.56) prior year
- Full-year net loss $57.3M ($2.74/diluted share) vs $6.3M loss ($0.30) prior year
- Full-year adjusted EBITDA -$15.4M vs +$0.7M prior year
- Goodwill impairment charge of $26.7M recorded in Q1 FY2026
- Board rejected two acquisition proposals at $4.00-$4.25/share, continuing as independent company
- Cash and cash equivalents $21.4M at March 31, 2026, down from $54.7M a year ago
- Operating cash flow -$28.4M for FY2026 vs +$4.7M prior year
Financial Impact
Revenue decline of 21.1% YoY to $179M, net loss widening to $57.3M from $6.3M, adjusted EBITDA swinging from +$0.7M to -$15.4M
Risk Factors
- Continued revenue decline and cash burn may necessitate equity or debt financing
- Whistleblower investigation costs and goodwill impairment signal operational and governance issues
- No acquisition premium materializing after board rejected proposals
- Negative adjusted EBITDA trajectory with no near-term path to profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305585 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | Press Release | $1.32 $1.26 | ▼ −4.55% | ▼ −4.97% | $1.22 (−7.58%) |
Sep 21, 2026 5w ago | 8-K | $1.60 $1.41 | ▼ −12.19% | ▼ −11.17% | $1.22 (−23.75%) |
Sep 17, 2026 5w ago | 8-K | $1.62 $1.56 | ▼ −4.01% | ▼ −4.61% | $1.22 (−24.69%) |
Sep 17, 2026 5w ago | Press Release | $1.62 $1.56 | ▼ −3.70% | ▼ −4.55% | $1.22 (−24.69%) |
Jun 26, 2026 17w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.30% | $1.22 (−32.97%) |
Jun 25, 2026 17w ago | DEFA14A | $1.76 $1.98 | ▲ +12.50% | ▲ +10.33% | $1.22 (−30.68%) |
Jun 2, 2026 20w ago | 8-K | $1.78 $1.72 | ▲ +3.37% | ▼ −0.45% | $1.22 (+31.46%) |
Jun 2, 2026 20w ago | Press Release | $1.78 $1.72 | ▲ +3.37% | ▼ −0.45% | $1.22 (+31.46%) |
May 29, 2026 21w ago | Press Release | $2.17 $1.68 | ▼ −22.58% | ▼ −20.06% | $1.22 (−43.78%) |
Apr 22, 2026 26w ago | Press Release | $2.23 $2.26 | ▲ +1.35% | ▼ −0.13% | $1.22 (−45.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers